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Restoration of anti-tumor immunity by blocking PD-
L1 signaling through the use of antibodies has proven
to be beneficial in cancer therapy. Here, we show
that BET bromodomain inhibition suppresses PD-L1
expression and limits tumor progression in ovarian
cancer. CD274 (encoding PD-L1) is a direct target
of BRD4-mediated gene transcription. In mouse
models, treatment with the BET inhibitor JQ1 signifi-
cantly reduced PD-L1 expression on tumor cells and
tumor-associated dendritic cells and macrophages,
which correlated with an increase in the activity of
anti-tumor cytotoxic T cells. The BET inhibitor limited
tumor progression in a cytotoxic T-cell-dependent
manner. Together, these data demonstrate a small-
molecule approach to block PD-L1 signaling. Given
the fact that BET inhibitors have been proven to be
safe with manageable reversible toxicity in clinical
trials, our findings indicate that pharmacological
BET inhibitors represent a treatment strategy for
targeting PD-L1 expression.INTRODUCTION
Tumors evade anti-tumor immunity by inhibitory pathways
that regulate the function of T lymphocytes, known as immune
checkpoints (Topalian et al., 2015). Programmed cell death
(PD)-1 protein is predominantly expressed on the surface of
T cells, while its ligands, such as PD-L1, are expressed on the
surface of both cancer cells and immune cells (Zou et al.,
2016). Interaction between PD-1 and PD-L1 inhibits T cell activ-
ity, which reduces T cell-mediated cytolysis. Therefore, inhibiting
this interaction could result in increased anti-tumor immunity.
Indeed, blockade of immune checkpoints by antibodies has
demonstrated remarkable activity in several cancer types (Ma-
honey et al., 2015). For example, antibody-based blockage of
PD-1 and PD-L1 signaling is therapeutically beneficial in an ex-
panding list of malignancies (Zou et al., 2016). Despite theseCell Report
This is an open access article under the CC BY-Nanti-tumor benefits, checkpoint blockade using these antibodies
is associated with unique adverse effects known as immune-
related adverse events (irAEs) due to nonspecific immunologic
activation (Naidoo et al., 2015). Prolonged immunosuppression,
often required to treat irAEs, predisposes patients to infections.
PD-L1 is associated with prognosis in several cancer types.
PD-L1 expression predicts a better prognosis in ovarian cancer
(Webb et al., 2016), which remains the most lethal gynecological
malignancy in the developed world. Blockade of PD-1/PD-L1
signaling enhances the amplitude of anti-tumor immunity in
ovarian cancer (Abiko et al., 2013; Cubillos-Ruiz et al., 2009).
PD-L1 expression correlates with clinical response to anti-
PD-1/L1 therapy (Zou et al., 2016). Despite the importance
of PD-L1 in tumor immunity, the regulation of PD-L1 expression
remains poorly understood. DNA hypomethylating agents such
as azacytidine increase PD-L1 expression in non-small-cell
lung cancer (Wrangle et al., 2013). This suggests that chromatin
modifiers, including writers, readers, and erasers (i.e., epigenetic
mechanisms), play a critical role in regulating PD-L1 expression.
Whether agents that target epigenetic regulators could be used
to inhibit PD-L1 signaling remains to be explored.
The bromodomain and extraterminal (BET) protein BRD4
directly binds to acetylated lysine on histone tails and other nu-
clear proteins to promote gene transcription by RNA polymerase
II (Pol II) (Filippakopoulos and Knapp, 2014). Specific BET inhib-
itors have been developed. Clinical trials in hematopoietic malig-
nancies have demonstrated the anti-tumor activity of BET inhib-
itors with a manageable toxicity prolife (Filippakopoulos and
Knapp, 2014). Here, we show that inhibition of BRD4 suppresses
PD-L1 expression and increases cytotoxic T cell activity to limit
tumor progression in vivo in ovarian cancer models. Our findings
establish an immune checkpoint targeting approach by repur-
posing existing pharmacological BET inhibitors.
RESULTS
BET Inhibitors Suppress PD-L1 Expression
Given the importance of targeting PD-L1 in anti-tumor immunity
and the poorly understood nature of its regulation, we evaluated
a panel of 24 small-molecule inhibitors known to target epigenetic
regulators (obtained fromTheStructureGenomicsConsortium) tos 16, 2829–2837, September 13, 2016 ª 2016 The Author(s). 2829
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
identify ‘‘hits’’ that suppress the expression of PD-L1. As upregu-
lation of PD-L1 is known to play a critical role in ovarian cancer
(Abiko et al., 2013), we focused on epithelial ovarian cancer
(EOC)cell lines.To identify suitablecellmodels for thesmall-mole-
cule screen,weexaminedPD-L1expression inapanel ofEOCcell
lines: PEO1, OVCAR3, OVCAR10, PEO4, and Kuramochi. PEO1
and OVCAR3 cells express high levels of PD-L1 (Figures S1A
and S1B) and were used for the screen. To limit the potential
bias introduced by variation in growth inhibition induced by the
small-molecule inhibitors, we established a growth inhibition
curve for each small-molecule inhibitor. We used the established
IC20 (inhibitory concentration 20%) value of each small-molecule
inhibitor (Table S1). The highest dose tested (20 mM)was used for
those inhibitors whose IC20 was not achieved (Figure 1A; Table
S1). Using flow-cytometric (fluorescence-activated cell sorting;
FACS) analysis, we measured the fold change in PD-L1 expres-
sion based on mean fluorescence intensity for each of the 24 in-
hibitors (Figure 1B). This analysis identified a list of five inhibitors
that significantly suppressed PD-L1 expression in PEO1 cells.
Similar analyses in OVCAR3 cells revealed a list of four inhibitors
that significantly suppressed PD-L1 expression (Figure S1C).
The top three ‘‘hits’’ for reducing PD-L1 expression in both cell
lines are BET inhibitors: JQ1, Bromosporine, and PFI-1 (Figures
1B and S1C). Inhibition of PD-L1 was specific to BET inhibitors,
but not bromodomain inhibitors in general, because other bromo-
domain inhibitors such as SGC-CBP30 did not significantly
reduce PD-L1 expression (Figure 1C).
Interferon-gamma (IFNg) induces PD-L1 expression. As a sec-
ondary screen, we determined the effects of the same panel of
epigenetic inhibitors on PD-L1 expression in cells treated with
IFNg (Figure 1D). This screen revealed that only the same three
BET inhibitors significantly suppressed PD-L1 expression in
the presence of IFNg stimulation (Figures 1D–1F). BET-inhibi-
tor-induced suppression of PD-L1 was not due to changes in
IFNg secretion because EOCcell lines did not secrete detectable
levels of IFNg, and JQ1 did not affect the secretion of IFNg (data
not shown). Thus, we identified BET inhibitors as suppressors of
PD-L1 expression.
BET Inhibition Reduces PD-L1 Expression at the
Transcriptional Level in a Dose- and Time-Dependent
Manner
As JQ1 is clinically applicable (known as TEN-010 in clinical
trials), we performed further validation on this inhibitor. We
demonstrated that JQ1 treatment decreased PD-L1 expression
with or without IFNg stimulation (Figures 2A and S2A). JQ1
reduced PD-L1 expression in a dose-dependent manner
(Figure 2B). Similar dose-dependent suppression of PD-L1
expression was also observed in IFNg-stimulated cells (Fig-
ure 2B). We also observed a time-dependent suppression
of PD-L1 expression by JQ1, where suppression of PD-L1
expression was observed 24 hr post-treatment (Figures 2C
and S2B). Notably, expression of CD274, the gene encoding
PD-L1, was reduced in a dose- and time-dependent manner
that mirrors PD-L1 downregulation induced by JQ1 (Figures
2D, 2E, and S2C). This indicates that suppression of PD-L1
expression by JQ1 occurs at the transcriptional level. Notably,
JQ1 reduced PD-L1 expression at a dose (e.g., 20 nM) that did2830 Cell Reports 16, 2829–2837, September 13, 2016not affect the growth of treated cells (Figures S2D and S2E).
This suggests that the observed reduction in PD-L1 expression
is not a consequence of growth inhibition induced by JQ1 (Fig-
ures 2B and 2E; Figures S2D and S2E). Therefore, we conclude
that JQ1 reduces PD-L1 expression at the transcriptional level in
a dose- and time-dependent manner.
CD274 Is a Direct Target Gene of BRD4
BRD4 is often amplified in ovarian cancer and is a major target of
JQ1 (Baratta et al., 2015; Goundiam et al., 2015). To determine
whether genetic knockdown of BRD4 directly regulates PD-L1
expression, BRD4 was knocked down using three individual
shRNAs (short hairpin RNAs), termed shBRD4s (Figures 3A
and 3B). All three shBRD4s efficiently knocked down BRD4
expression and decreased PD-L1 expression (Figures 3A–3D).
Similar results were observed in multiple EOC cell lines (Figures
S3A–S3C). The observed decrease in PD-L1 expression was
rescued by the expression of a shBRD4-resistant wild-type
BRD4 (Figures 3E and 3F). In addition, BRD4 knockdown also
reduced PD-L1 expression in IFNg-stimulated cells (Figure 3G).
Next, we profiled the global changes in mRNA expression
induced by JQ1 or shBRD4 in PEO1 cells by QuantSeq (GEO:
GSE81698). Notably, CD274 expression was downregulated
4-fold by both JQ1 and shBRD4 in this analysis (Figure S3D).
Pathway enrichment analysis on significantly changed genes re-
vealed biological processes, including lymphocyte chemotaxis
and inflammatory response (Table S2).
We next determined whether BRD4 correlates with PD-L1
expression in EOC. Using a panel of EOC cell lines, we observed
a trend toward a positive correlation between BRD4 and PD-L1
expression (Figure 3H). We examined whether BRD4 andCD274
expression is positively correlated in EOC specimens. We
used a published database that profiled gene expression in 53
cases of laser capture and microdissected (LCM) high-grade
serous EOCs (Mok et al., 2009). Indeed, there was a significant,
positive correlation between BRD4 and CD274 in EOCs (Fig-
ure 3I, p < 0.0001).
Next, we determined whether CD274 is a direct target gene
of BRD4. BRD4 chromatin immunoprecipitation (ChIP) followed
by next-generation sequencing (ChIP-seq) in OVCAR3 cells
revealed that BRD4 is enriched at the CD274 gene promoter
(Figure S3E). ChIP analysis showed a significant association
of BRD4 with the CD274 promoter, which was decreased with
JQ1 treatment (Figures 3J and S3F). Notably, JQ1 treatment
did not significantly reduce acetylated H3 levels at the CD274
promoter (Figure 3K). The observed JQ1-mediated suppression
of PD-L1 correlated with decreased association of RNA Pol II
with the CD274 promoter (Figure 3L). Next, we determined
whether upregulation of PD-L1 expression by IFNg correlates
with increased association of BRD4 at the CD274 promoter.
Indeed, IFNg treatment enhanced the association of BRD4
with the CD274 promoter, which was reduced by JQ1 treatment
(Figure 3M). This was not due to the upregulation of BRD4 by
IFNg, because we did not observe an increase in BRD4 protein
expression in cells treated with IFNg (Figure 3N). Together, these
data support the notion that CD274 is a direct target gene of
BRD4, which is subject to JQ1-mediated repression at the tran-
scriptional level (Figure 3O).
Figure 1. BET Inhibitors Suppress PD-L1
Expression in Ovarian Cancer Cells
(A) Flow diagram of experimental design.
(B) Plot of the ratio of PD-L1 expression on PEO1
cells treatedwith doses of the indicated epigenetic
inhibitors or vehicle controls as detailed in Table
S1. *p < 0.04; **p < 0.0001.
(C) Representative changes in PD-L1 expression
determined by FACS on PEO1 cells treated
with the indicated BET inhibitors. SGC-CBP30
was used as a negative control.
(D) Same as in (B) but for IFNg-stimulated
(20 ng/ml, 24 hr) PEO1 cells. *p < 0.02; **p < 0.002.
(E) Representative changes in PD-L1 expression
determined by FACS on PEO1 cells stimulated
with IFNg (20 ng/ml, 24 hr) and treated with the
indicated BET inhibitors. SGC-CBP30 was used
as a negative control.
(F) Venn diagram of ‘‘hits’’ that suppress PD-L1
expression from the three indicated screens.
Error bars represent SEM of three independent
experiments. See also Figure S1 and Table S1.
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Figure 2. BET Inhibitor JQ1 Suppresses PD-
L1 Expression at the Transcriptional Level
(A) PEO1 cells stimulated with or without IFNg
(20 ng/ml, 24 hr) were treated with or without
200 nM JQ1 for 72 hr. PD-L1 expression was
determined by FACS.
(B) PEO1 cells with or without IFNg (20 ng/ml,
24 hr) stimulation were treated with indicated
doses of JQ1 for 72 hr. PD-L1 expression was
determined by FACS.
(C) PEO1 cells were treated with 200 nM JQ1. PD-
L1 expression was determined by FACS at the
indicated time points.
(D) PEO1 cells were treated with 200 nM JQ1.
mRNA expression of CD274 (encoding PD-L1)
was determined by qRT-PCR at the indicated time
points. *p < 0.05.
(E) PEO1 cells were treated with the indicated
doses of JQ1 for 72 hr, and CD274 (encoding
PD-L1) mRNA expression was determined by
qRT-PCR. *p < 0.05.
Error bars represent SEM of three independent
experiments. See also Figure S2.The BET Inhibitor JQ1 Limits Tumor Progression in a
Cytotoxic T Cell-Dependent Manner
Besides tumor cells, PD-L1 is expressed on tumor-associated
immune cells, such as regulatory dendritic cells (DCs) and mac-
rophages in ovarian cancer (Scarlett et al., 2012). Notably, PD-L1
expression on both DCs andmacrophages and the tumor cells is
important for evading anti-tumor immunity (Zou et al., 2016).
Therefore, we determined that JQ1 decreased PD-L1 expression
on mouse bone-marrow-derived DCs (BMDCs) (Figure S4A).
To determine the effects of BET inhibitors on PD-L1 expres-
sion and anti-tumor immunity in vivo, we utilized the ID8-
Defb29/Vegf-a syngeneic mouse model. This model recapitu-
lates the aggressive inflammatory microenvironment of human
ovarian carcinomas, and PD-L1 signaling is critical for cancer
progression in this model (Cubillos-Ruiz et al., 2009). For in vivo
experiments, the injected mice were allowed to develop ascites
for 7 days and treated with 50mg/kg JQ1 or vehicle control twice
weekly for 18 additional days (Figure 4A). PD-L1 expression on
both immune and tumor cells from peritoneal washes was exam-
ined. Indeed, there was a significant decrease in PD-L1 expres-
sion on immune cells such as DCs and macrophages isolated
from JQ1 treated mice compared with controls (Figures 4B
and 4C). PD-L1 expression on the tumor cells was also signifi-
cantly reduced by JQ1 treatment (Figures 4B and 4C). Notably,
the observed JQ1-mediated reduction in PD-L1 expression on
tumor cells was overcome by overexpressing CD274 in tumor
cells (Figures 4D and S4B). As a control, CD274 overexpression
in tumor cells did not affect the suppression of PD-L1 expression
by JQ1 in DCs (Figure S4C). This indicates that the observed2832 Cell Reports 16, 2829–2837, September 13, 2016reduction in PD-L1 by JQ1 in vivo is due
to its suppression of endogenous PD-L1
instead of an indirect effect. The dose of
JQ1 used was significantly lower than
those of previous studies (Filippakopou-
los et al., 2010), which did not signifi-cantly reduce the percentage of CD8+ cytotoxic T cells (Figures
S4D and S4E). Therefore, we can achieve a dose of JQ1 that
suppresses PD-L1 expression on both immune cells, such as
DCs and macrophages, and tumor cells without affecting the
survival of cytotoxic T cells.
Next, we determined the effects of JQ1 on CD8+ cytotoxic
T cell activity. We observed an increased number of tumor-asso-
ciated T cells that secreted Granzyme B, as determined by
enzyme-linked immunospot (ELISpot) analysis in JQ1-treated
mice compared to controls (Figures 4E and 4F). Similar results
were also obtained with an independent syngeneic mouse
model using the UPK10 cell line (Figures S4G and S4H). Consis-
tently, JQ1 treatment increased the percentage of IFNg-produc-
ing CD8+ cytotoxic T cells (Figures 4G and 4H). Together, these
findings support the notion that JQ1 treatment suppresses
PD-L1 expression on both immune and tumor cells in vivo and
increases CD8+ cytotoxic T activity.
We next determined the effects of JQ1 treatment on tumor
growth in vivo. JQ1 significantly suppressed tumor growth in
an orthotopic ID8-luciferase syngeneic mouse model (Figures
4I, 4J, and S4I). Significantly, the observed tumor-suppressive
effects are CD8+ T cell dependent because antibody-mediated
depletion of CD8+ T cells abrogated the therapeutic benefit of
JQ1 treatment (Figures 4I and 4J). In addition, JQ1 treatment
significantly improved the survival of mice receiving adoptively
transferred tumor-reactive T cells in an orthotopic UPK10 synge-
neic mouse model (Figure 4K). Together, these data support the
notion that BET inhibition limits the progression of ovarian cancer
in a CD8+ cytotoxic T cell-dependent manner.
Figure 3. CD274 Is a Direct Target Gene of BRD4
(A) PEO1 cells expressing shBRD4 or control were examined for BRD4 expression by qRT-PCR. *p < 0.05.
(B) Same as in (A) but examined for the expression of BRD4 protein by immunoblotting.
(C) Same as in (A) but examined for CD274 mRNA expression by qRT-PCR. *p < 0.05.
(D) Same as in (A). PD-L1 expression was determined by FACS.
(E) PEO1 cells expressing shBRD4 (#3) that targets the 30 UTR region of the humanBRD4 gene with or without simultaneous expression of a wild-typeBRD4 open
reading frame. BRD4 and Vinculin expression was determined by immunoblot.
(F) Same as in (E) but examined for PD-L1 expression by FACS.
(G) PEO1 cells expressing shBRD4 (#3) or control with or without IFNg (20 ng/ml, 24 hr) stimulation were examined for PD-L1 expression by FACS.
(H) Expression of BRD4, PD-L1, and b-actin were examined in the indicated ovarian cancer cell lines or normal human ovarian surface epithelial (HOSE) cells by
immunoblot.
(I) Correlation between BRD4 and CD274 expression was determined by Spearman statistical analysis in 53 cases of laser capture and microdissected high-
grade serous ovarian cancer specimens.
(legend continued on next page)
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DISCUSSION
Several BET inhibitors are now in clinical development for a
number of cancer types (Filippakopoulos and Knapp, 2014).
Although anti-PD-L1 antibody therapy is generally well tolerated,
it is known to trigger irAEs—in particular, with prolonged treat-
ment (Naidoo et al., 2015). Missing from immunotherapy are
traditional small-molecule drugs that may offer several unique
advantages (Adams et al., 2015). Our findings raise the possibil-
ity of targeting PD-L1 using BET inhibitors. BET inhibitors
suppress macrophage inflammatory responses and attenuate
systematic inflammatory processes (Belkina et al., 2013; Nico-
deme et al., 2010). Thus, it is possible that BET inhibitors may
quell the inflammatory response without eliminating the anti-tu-
mor immune response.
PD-L1-positive myeloid cells play a key role in human ovarian
cancer (Curiel et al., 2004). BET inhibitors affect PD-L1 expres-
sion in both tumor cells and in myeloid DCs and macrophages
(Figures 4 and S4). Therefore, BET inhibitors suppress PD-L1
expression in both host antigen-presenting cells and tumor cells.
Compared with immune-associated PD-L1, oncogenic PD-L1
and its role in tumor immunity remain poorly defined (Zou
et al., 2016). Interestingly, BET inhibitors suppress PD-L1
expression in tumor cells with or without IFNg stimulation (Fig-
ures 2 and S2). Thus, this mechanism may couple oncogenic
and immune-associated PD-L1 regulation.
Identification of potential biomarkers that predict the response
to anti-PD-L1 therapy in cancer remains a clinical challenge (Me-
lero et al., 2015). In particular, patients who positively respond to
anti-PD-L1 therapy despite a lack of PD-L1 expression highlight
the complex regulation of PD-L1 in cancer (Brahmer et al., 2015).
Our findings establish that BRD4 is a critical regulator of PD-L1
expression, as BRD4 inhibition blocks the IFNg-induced upregu-
lation of PD-L1 (Figures 2 and 3). This suggests that BRD4
expression may dictate how well PD-L1 can be induced in
response to signals from the tumor microenvironment.
BRD4 is localized to 19p13.1. This BRD4 locus is often ampli-
fied in ovarian cancer (Goundiam et al., 2015). In fact, ovarian
cancer shows one of the highest BRD4 amplification rates in all
cancer types based on The Cancer Genome Atlas (TCGA) data-
base (data not shown). BRD4 expression positively correlates
with CD274 expression in ovarian cancer specimens (Figure 3I).
However, the existence of tumors with high BRD4 expression
and low CD274 expression suggests that additional cell-intrinsic
or -extrinsic mechanisms may also regulate CD274 expression.
Nonetheless, it will be interesting to correlate the response to
anti-PD-L1 blockade therapy with BRD4 amplification or expres-
sion. Notably, BRD4 also promotes survival and proliferation of
ovarian cancer cells (Baratta et al., 2015). Therefore, BET inhib-
itors may have dual anti-tumor effects on both tumor cells as well
as the tumor-promoting immune environment.(J–L) PEO1 cells were treated with or without 200 nM JQ1 for 24 hr. The cells were
(L). An isotype-matched IgG was used as a negative control. The association wit
(M) Same as in (J), but for PEO1 cells with or without IFNg (20 ng/ml, 24 hr) stim
(N) Same as in (M) but examined for BRD4 and b-actin protein expression by im
(O) A model for BRD4-mediated regulation of PD-L1 expression.
Error bars represent SEM of three independent experiments. See also Figure S3
2834 Cell Reports 16, 2829–2837, September 13, 2016Our findings demonstrate that BET inhibitors suppress PD-L1
expression, which correlates with an increase in cytotoxic T cell
activity. A limitation of the study is that BET inhibition affects the
expression of other genes in addition toCD274 (Figure S3; Table
S2). Changes in the expression of other genes could also
contribute to the observed anti-tumor effects. However, we pre-
viously demonstrated that decreased PD-L1 in myeloid cells,
smaller than those elicited by JQ1, are sufficient to have anti-tu-
mor immune responses (Cubillos-Ruiz et al., 2009). Therefore,
our data support the notion that downregulation of PD-L1 plays
a significant role in the observed anti-tumor immune response
induced by JQ1. Given the demonstrated broad applicability of
PD-L1 blockade therapy in human cancer, we anticipate our
findings to have far-reaching implications for developing future
combinatory cancer therapies.
EXPERIMENTAL PROCEDURES
In Vivo Syngeneic Mouse Model
All animal protocols described in this study were approved by the Institutional
Animal Care and Use Committee (IACUC) at The Wistar Institute. Six- to eight-
week-old female wild-type C57BL/6 mice were purchased from Charles River
Laboratories. ID8 cells were provided by K. Roby (Department of Anatomy and
Cell Biology, University of Kansas) and retrovirally transduced to express
Defb29 and Vegf-a (Conejo-Garcia et al., 2004). Mouse ovarian tumor
UPK10 cells were described previously (Scarlett et al., 2012). The ID8-
Defb29/Vegf-a intraperitoneal (i.p.) tumor model was generated as previously
described (Conejo-Garcia et al., 2004). Briefly, 2 3 106 70% confluent ID8-
Defb29/Vegf-a cells were injected into the peritoneal cavity of mice and al-
lowed to establish tumors. After 1 week, mice were randomized into two
groups and treated twice a week with 50 mg/kg JQ1 or vehicle control by
i.p. injection for 3 weeks.
Foranti-CD8antibody treatment, 23106 luciferase-expressing ID8cellswere
orthotopically transplanted intoC57BL/6miceby i.p. injection. The transplanted
tumors were allowed to establish for 22 days. The mice were then randomized
and treated intraperitoneally with 50 mg/kg JQ1 twice a week with or without
an anti-CD8 antibody, 500 mg per mouse, once a week. Tumor growth was fol-
lowed by non-invasive imaging, as previously described (Bitler et al., 2015), us-
ing an IVIS Spectrum. Images were analyzed using Live Imaging 4.0 software.
Tumor-Reactive T Cell-Adoptive Immunotherapy
T cells from tumor-freemicewere primedwith tumor-antigen-pulsedBMDCs as
described previously (Nesbeth et al., 2009). Briefly, BMDCs were pulsed over-
night with g-irradiated (10,000 rad) and UV-treated (30 min) UPK10 tumor cells
at a ratio of 10:1 (dendritic cells:tumor cells). Tumor-antigen-pulsed BMDCs
were then co-cultured with T cells at a 1:10 (BMDC:T cell) ratio in the presence
of interleukin 2 (IL-2; 10 U/ml) and interleukin 7 (IL-7; 1 ng/ml) (both from Pepro-
Tech) for 7 days. FemaleC57BL/6mice (6–8weeks old)were intraperitoneally in-
jected with 23 106 UPK10 tumor cells and treated intraperitoneally with JQ1 or
vehicle control on day 5 and day 12. 13 106 tumor-antigen-primed T cells were
transferred into tumor-bearing mice on day 7 and day 14 post-tumor challenge.
Statistical Analysis
GraphPad Prism Version 5.0was used to perform statistical analyses. The Stu-
dent’s t test was used to determine p values of raw data. A p value <0.05 was
considered as significant.subjected to ChIP analysis using antibodies against BRD4 (J), H3Ac (K), or Pol II
h the CD274 gene promoter was quantified by qPCR. #p > 0.05; *p < 0.05.
ulation were treated with JQ1. *p < 0.05.
munoblot.
and Table S2.
Figure 4. JQ1 Decreases PD-L1 Expression and Limits Tumor Progression in a Cytotoxic T Cell-Dependent Manner In Vivo
(A) Flow diagram of experimental design. These experiments were repeated three times.
(B) 23 106 total cells from peritoneal wash were subjected to staining using antibodies against CD45.2-PE/Cy7, CD11c-APC/Cy7, F4/80-PerCP/Cy5.5, MHCII-
PE, and PDL1-APC. PD-L1 expression was determined by FACS. CD45.2-PE/Cy7-negative cells were gated as tumor cells. Among CD45.2-PE/Cy7-positive
cells, MHCII and CD11c double-positive cells were gated as dendritic cells, while MHCII- and F4/80-positive cells were gated as macrophages.
(C) Quantification of PD-L1 expression in indicated cell populations.
(D) C57BL/6 mice were injected intraperitoneally with ID8-Defb29/Vegf-a cells with or without CD274 overexpression. Mice were randomized and treated with
50 mg/kg JQ1 twice every week for 18 days or vehicle controls. Cells from peritoneal wash were subjected to analysis for PD-L1 expression using the same
approach as detailed in (B). Shown is PD-L1 expression in tumor cells (CD45.2-PE/Cy7 negative) from the indicated groups. Due to low cell numbers, cells from
five mice in each of the indicated groups were combined for FACS analysis.
(legend continued on next page)
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